SEC Filing Summary: Billiontoone, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Billiontoone, Inc. on November 10, 2025, covering events occurring on November 7, 2025. The filing documents the closing of the Company's Initial Public Offering (IPO) and the concurrent amendment of its governing corporate documents.
Key Financial Metrics
- IPO Proceeds: The Company sold an aggregate of 5,233,765 shares of Class A Common Stock.
- Offering Price: $60.00 per share.
- Gross Proceeds: Approximately $314.0 million (before underwriting discounts, commissions, and offering expenses).
- Underwriters' Option: The underwriters exercised their option in full to purchase an additional 682,665 shares.
- Operating Metrics: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the transition to a publicly traded entity on The Nasdaq Stock Market LLC under the symbol "BLLN." Additionally, the Company filed an amended and restated Certificate of Incorporation and Bylaws with the State of Delaware, effective upon the IPO closing.
Outlook, Risks, and Management Commentary
The filing confirms the successful completion of the IPO as described in the final prospectus dated November 5, 2025. It references the "Description of Capital Stock" section of the Prospectus for details on the amended corporate governance provisions. The filing does not contain specific forward-looking guidance, risk factors, or management commentary beyond the confirmation of the transaction closing.
Key Facts for Investor Verification
- Verify the net proceeds after deducting underwriting discounts and offering expenses, as only gross proceeds ($314.0 million) are stated.
- Review the Amended and Restated Certificate of Incorporation (Exhibit 3.1) and Bylaws (Exhibit 3.2) for specific governance changes.
- Confirm the final share count and any lock-up agreements not detailed in this summary.
- Check the final prospectus (File No. 333-290761) for detailed risk factors and use of proceeds.